Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance

Reproductive BioMedicine Online

Volumn 12, Issue 6, 2006, Pages 669-683

  Ulloa Aguirre, Alfredo ^a   Portocarrero, Lesly ^b   Zariñán, Teresa ^a   Olivares, Aleida ^c   Carranza Lira, Sebastián ^a   Veldhuis, Johannes D ^d   López Alvarenga, Juan C ^e  

^a Hospital Luis Castelazo Ayala   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d MAYO CLINIC   (United States)

^e SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Insulin resistance; LH; Metformin; Polycystic ovarian syndrome; Testosterone

Indexed keywords

GLUCOSE; GONADORELIN; INSULIN; LUTEINIZING HORMONE; METFORMIN; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; FEEDBACK SYSTEM; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; NEUROENDOCRINE DISEASE; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT IDENTIFICATION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

EID: 33745049764     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61079-6     Document Type: Article

References (79)

1. Adashi EY, Hsueh AJ, Yen SS 1981 Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108, 1441-1449.
2. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ et al. 2002 Prevalence and characteristics of early-onset type 2 diabetes in Mexico. American Journal of Medicine 113, 569-574.
3. Arantes GA, Soares JM, Leme E et al. 2004 Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility 81, 355-360.
4. Arroyo A, Laughlin GA, Morales AJ, Yen SSC 1997 Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. Journal of Clinical Endocrinology and Metabolism 82, 3728-3733.
5. Attia GR, Raine WE, Carr BC 2001 Metformin directly inhibits androgen production in human thecal cells. Fertility and Sterility 76, 517-524.
6. Azziz R, Woods KS, Reyna R et al. 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 89, 2745-2749.
7. Berga SL, Yen SSC 1989 Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clinical Endocrinology (Oxf) 30, 177-184.
8. Berga SL, Guzick DS, Winters SJ 1993 Increased luteinizing hormone and α-subunit secretion in women with hyperandrogenic anovulation. Journal of Clinical Endocrinology and Metabolism 77, 895-901.
9. Bergendah M, Veldhuis JD 2001 Is there a physiological role for gonadotorphin oligosaccharide heterogeneity in humans? III. Luteinizing hormone heterogeneity: a medical physiologist's perspective. Human Reproduction 16, 1058-1064.
10. Buckler HM, Phillips SE, Cameron IT et al. 1988 Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 67, 300-306.
11. Burger CW, Korsen T, Van Kessel H et al. 1985 Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease and non-PCOD secondary amenorrhea. Journal of Clinical Endocrinology and Metabolism 61, 1126-1132.
12. Castro-Fernández C, Olivares A, Söderlund D et al. 2000 A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropin-releasing hormone-releasable luteinizing hormone in obese men. Journal of Clinical Endocrinology and Metabolism 85, 4603-4610.
13. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R 2005 Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertility and Sterility 83, 1717-1723.
14. Cheung AP, Chang RJ 1995 Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women. Human Reproduction 10, 1054-1059.
15. Dahlgren E, Janson PO, Johansson S et al. 1992 Polycystic ovary syndrome and risk for myocardial infraction-evaluated from a risk factor model based on a prospective study of women. Acta Obstetrica et Gynecologica Scandinavica 71, 599-604.
16. Daniels TL, Berga SL 1997 Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. Journal of Clinical Endocrinology and Metabolism 82, 4179-4183.
17. Diao F-Y, Xu M, Hu Y et al. 2004 The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. Journal of Molecular Endocrinology 33, 59-72.
18. Ding YQ, Huhtaniemi I 1991 Preponderance of basic isoforms of serum luteinizing hormone (LH) is associated with high bio/immuno ratio of LH in healthy women and women with polycystic ovarian disease. Human Reproduction 6, 346-350.
19. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocrine Reviews 18, 774-800.
20. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, 1165-1174.
21. Eagleson CA, Bellows AB, Hu K et al. 2003 Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids. Journal of Clinical Endocrinology and Metabolism 88, 5158-5162.
22. Ehrmann DA 2005 Polycystic ovary syndrome. New England Journal of Medicine 352, 1223-1236.
23. Ehrmann DA, Barnes RB, Rosenfield RL et al. 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141-146.
24. Ehrmann DA, Cavaghan MK, Imperial J et al. 1997 Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82, 524-530.
25. Escobar-Morreale, HF, Luque-Ramírez M, San Millán JL 2005 The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews 26, 251-282.
26. Evans WS, Sollenberger MJ, Booth RA Jr et al. 1992 Contemporary aspects of discrete peak-detection algorithms. II. The paradigm of the luteinizing hormone pulse signal in women. Endocrine Reviews 13, 81-104.
27. Fiad TM, Cunningham SK, McKenna TJ 1996 Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. European Journal of Endocrinology 135, 335.
28. Fleming R 2005 Recruitment prior to ovarian stimulation: ways of improving follicular recruitment. Reproductive BioMedicine Online 10, 55-59.
29. García-Rudaz MC, Ropelato G, Escobar ME et al. 1998 Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome. European Journal of Endocrinology 139, 621-630.
30. Genazzani AD, Battaglia C, Malavasi B et al. 2004 Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertility and Sterility 81, 114-119.
31. Gilling-Smith C, Story H, Rogers V, Franks S 1997 Evidence for a primary abnormality of theca cell steroidogenesis in the polycystic ovary syndrome. Clinical Endocrinology (Oxford) 47, 93-99.
32. Grulet H, Hecart AC, Delemer B et al. 1993 Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clinical Endocrinology (Oxford) 38, 621-626.
33. Hung YNE, Ming SWA, Cung HP 2001 Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Human Reproduction 16, 1625-1631.
34. Keenan DM, Alexander SL, Irvine CHG et al. 2004 Reconstruction of in-vivo time-evolving neuroendocrine dose-response properties unveils admixed deterministic and stochastic elements in interglandular signaling. Proceedings of the National Academy of Sciences of the USA 101, 6740-6745.
35. Keenan DM, Sun W, Veldhuis JD 2000 A stochastic biomathematical model of the male reproductive hormone system. SIAM Journal on Applied Mathematics 61, 934-965.
36. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L 2000 Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertility and Sterility 73, 1149-1154.
37. la Marca A, Morgante G, Palumbo M et al. 2002 Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. Fertility and Sterility 78, 1234-1239.
38. la Marca A, Obinchemti Egbe T, Morgante G et al. 2000 Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Human Reproduction 15, 21-23.
39. Legro RS, Kunselman AR, Dunaif A 2001 Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 117, 607-613.
40. Legro RS, Finegood D, Dunaif A 1998 A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83, 2694-2698.
41. López-Alvarenga JC, Zariñán T, Olivares A et al. 2002 Poorly controlled type I diabetes mellitus in young men selectively suppresses luteinizing hormone secretory burst mass. Journal of Clinical Endocrinology and Metabolism 87, 5507-5515.
42. Mehta RV, Patel KS, Coffler MS et al. 2005 Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism 90, 2136-2141.
43. Moghetti P, Castello R, Negri C et al. 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism 85, 139-146.
44. Morales AJ, Laughlin GA, Butzow T et al. 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. Journal of Clinical Endocrinology and Metabolism 81, 2854-2864.
45. Morin-Papunen LC, Vauhkonen I, Koivunen RM et al. 2000 Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology and Metabolism 85, 3161-3168.
46. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK 1998a Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertility and Sterility 69, 691-696.
47. Morin-Papunen LC, Koivunen RM, Tomás C et al. 1998b Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83, 2566-2568.
48. Mulligan T, Iranmanesh A, Johnson ML et al. 1997 aging alters feed-forward and feedback linkages between LH and testosterone in healthy men. American Journal of Physiology 42, R1407-R1413.
49. Nagami M, Osuampke C, Kelver ME 1999 Increased bioactive luteinizing hormone levels and bio/immuno ratio in women with hyperthecosis of the ovaries: possible role of hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 84, 1685-1689.
50. Nestler JE, Jakubowicz DJ 1997 Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. Journal of Clinical Endocrinology and Metabolism 82, 4075-4079.
51. Ortega-González C, Cardoza L, Coutiño B et al. 2005 Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. Journal of Endocrinology 184, 233-239.
52. Paradisi G, Steinberg HO, Hempfling A 2001 Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103, 1410-1405.
53. Parra A, Ramírez A, Espinoza de los Monteros A 1994 Fasting glucose/ insulin ratio. An index to differentiate normo- from hyperinsulinemic women with polycystic ovary syndrome. Revista de Investigación Clínica 46, 363-368.
54. Pastor CL, Griffin-Korg ML, Aloi JA et al. 1998 Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. Journal of Clinical Endocrinology and Metabolism 83, 582-590.
55. Patel K, Coffler MS, Dahan MH et al. 2003 Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. Journal of Clinical Endocrinology and Metabolism 88, 5456-5461.
56. Pincus SM 1991 Approximate entropy as a measure of system complexity. Proceedings of the National Academy of Sciences of the USA 88, 2297-2301.
57. Pincus SM, Hartman ML, Roelfsema F et al. 1999 Hormone pulsatility discrimination via coarse and short time sampling. American Journal of Physiology 277, E948-E957.
58. Pincus SM, Veldhuis JD, Mulligan T et al. 1997 Effects of age on the irregularity of LH and FSH serum concentrations in women and men. American Journal of Physiology 274, E898-E995.
59. Pirwany IR, Yates RWS, Cameron IT, Fleming R 1999 Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligoamenorrhoea. Human Reproduction 14, 2963-2968.
60. Rebar R, Judd HL, Yen SSC, Rakoff J et al. 1976 Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. Journal of Clinical Investigation 57, 1320-1329.
61. South SA, Asplin CM, Carlsen EC et al. 1993 Alterations in luteinizing hormone secretory activity in women with insulin-dependent diabetes mellitus and secondary amenorrhea. Journal of Clinical Endocrinology and Metabolism 76, 1048-1053.
62. Spritzer PM, Poy M, Wiltgen D et al. 2001 Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements. Human Reproduction 16, 1340-1346.
63. Taylor AE, McCourt B, Martin KA et al. 1997 Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82, 2248-2256.
64. Velazquez EM, Mendoza S, Hamer T et al. 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43, 647-654.
65. Veldhuis JD, Johnson ML 1992 Deconvolution analysis of hormone data. Methods in Enzymology 210, 539-575.
66. Veldhuis JD, Johnson ML 1986 Cluster analysis: a simple, versatile and robust algorithm for endocrine pulse detection. American Journal of Physiology 250, E486-E493.
67. Veldhuis JD, Johnson ML, Veldhuis OL et al. 2001a Impact of pulsatility of the ensemble orderliness (approximate entropy) of neurohormone secretion. American Journal of Physiology 281, R1975-R1985.
68. Veldhuis JD, Pincus SM, García-Rudaz M et al. 2001b Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 86, 72-79.
69. Veldhuis JD, Pincus SM, García-Rudaz MC et al. 2001c Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 86, 3772-3778.
70. Veldhuis JD, Straume M, Iranmanesh A et al. 2001d Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. American Journal of Physiology 280, R721-R279.
71. Veldhuis JD, Johnson ML, Faunt LM, 1994 Assessing temporal coupling between two, or among three or more, neuroendocrine pulse trains: cross-correlation analysis, simulation methods, and conditional probability testing. Methods in Neuroscience 20, 336-376.
72. Veldhuis JD, Carlson ML, Johnson ML 1987 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proceedings of the National Academy of Sciences of the USA 84, 7686-7690.
73. Venturoli S, Porcu E, Fabbri R et al. 1988 Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clinical Endocrinology (Oxf) 28, 90-107.
74. Vigersky RA, Filmore-Nassar A, Glass AR 2006 Thyrotropin suppression by metformin. Journal of Clinical Endocrinology and Metabolism 91, 225-227.
75. Waldstreicher J, Santoro NF, Hall JE et al. 1988 Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. Journal of Clinical Endocrinology and Metabolism 66, 165-172.
76. Wood JR, Nelson VL, Ho C et al. 2003 The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. Journal of Biological Chemistry 278, 26380-26390.
77. Yen SSC, Vela P, Rankin J 1970 Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 30, 435-442.
78. Zambrano E, Zariñán T, Olivares A et al. 1999 Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems. Endocrine 10, 113-121.
79. Zariñán T, Olivares A, Söderlund D et al. 2001 Changes in the biological: immunological ratio of basal and GnRH-releasable FSH during the follicular, pre-ovulatory, and luteal phases of the human menstrual cycle. Human Reproduction 16, 1611-1618.